SOURCE-LINKED STUDY SUMMARY
Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes
Sponsor announcement summarizedQuality not appraised
- What was studied
- Preliminary ZUPREME-2 results tested an amylin analog against placebo.
- Who / model studied
- 220 adults with overweight/obesity and type 2 diabetes.
- Studied dose & schedule
- Weekly subcutaneous petrelintide, with escalation, versus placebo for 28 weeks. Milligram targets were not disclosed.
- What the study found
- Sponsor-reported weight loss was 7.4–9.2% versus 2.0%, using the efficacy estimand. Placebo-adjusted HbA1c reduction was 0.61–0.88 percentage points. GI-related discontinuation: 1.9% versus 1.7%.
- Limitations & context
- Not yet a peer-reviewed full report. Treatment-regimen estimates were described as consistent but not quantified. Missing confidence intervals and detailed safety tables; no head-to-head GLP comparison.
Read summary source ↗ · Prepared 10/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: sponsor announcement, full poster not reviewed. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.